Welcome to the 3rd Annual Blood-Brain Barrier Summit

Dedicated to Helping You Enhance Drug Delivery Across the Blood-Brain Barrier to Enable Effective Treatments for Neurodegenerative Diseases

The blood-brain barrier (BBB) is an extremely complex interface brimming with tricks and secrets we need to elucidate.

Now in its 3rd year, the Blood-Brain Barrier Summit is the industry’s definitive blood-brain barrier conference, focused exclusively on evaluating innovative approaches to tackling the single biggest challenge for CNS drug developers.

Whatever approach you are working on, we have collated a comprehensive variety of topics to showcase the latest scientific advances across this very competitive field.

Building on the success of last year’s meeting, this year’s program will uncover how leading companies and academics are working to enhance BBB penetration through the use of antibody therapies, nanoparticle engineering, AAV capsids, focused ultrasound, extracellular vesicles and more! New for this year we also explore the mechanisms of SARS-CoV-2 brain entry.

As we gather the best minds in this ever-challenging field, from the likes of AbbVie, Novartis, Roche, Merck and Ossianix, join this intimate forum to be part of the conversation focused on enhancing drug delivery across the blood-brain barrier and network and build meaningful partnerships with over 80 blood-brain barrier specialists.

Meet the Expert Speaker Faculty

Amber D. Van Laar

VP Clinical Development

Asklepios BioPharmaceutical, Inc.

Jonathan Sugam

Associate Principal Scientist, Neuroscience Discovery

Merck

Nathalie Agar

Associate Professor of Neurosurgery & Radiology

Harvard Medical School

Nathalie Cartier

Head of NeurogenCell Lab, Paris Brain Institute (ICM), INSERM, Paris Sorbonne University, CNS Expert

Asklepios BioPharmaceutical, Inc.

William A. Banks

Associate Chief of Staff - Research & Development, VA Puget Sound Professor, Division of Gerontology & Geriatric Medicine, Department of Medicine

University of Washington

Danica Stanimirovic

Director, Translational Bioscience, Human Health Therapeutics Research Centre

National Research Council of Canada

Felix Schumacher

Program Leader Targeted Therapeutics

Roche

Pawel Stocki

Director of Research

Ossianix

Stina Syvänen

Associate Professor

Uppsala University

Sungwon An

Director

ABL Bio

Testimonials From the Blood-Brain Barrier Community

Perfect organization that allowed great interactions with an engaged virtual audience
Roberto Villasenor Solorio, Head of Lab, Roche

"Network and collaborate with academic and industry experts to find solutions for key barriers to progress the field of therapeutic delivery across the BBB"
- Danica Stanimirovic, Director - Translational Bioscience, Human Health Therapeutics & Research Centre, National Research Council, Canada

It was a great chance to hear directly about current trends, what the field wants to move forward, and what the field is concerned about.”
- Sungwon An, Director, ABL Bio Inc

"Very good overview to understand what drives the field and where the cutting edge is.”
- Felix Schumacher, Senior Scientist - Large Molecule Research, Roche

More From the World CNS Event Series